This week we sit down virtually with Dr. Atle Fretheim, Research Director of the Norwegian Institute of Public Health, to talk about how Norway has responded to the COVID-19 crisis - specifically, how they've handled it when it comes to public schools. We also have an interview with Dr. Anthony "Tony" Letai of the Dana Farber Cancer Center on cancer biology. 

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.17 COVID-19 and Schools in Norway with Dr. Atle Fretheim & Cancer Biology with Dr. Anthony Letai

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.17 COVID-19 and Schools in Norway with Dr. Atle Fretheim & Cancer Biology with Dr. Anthony Letai

Download our free app to listen on your phone